Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1831948 | 0.80 | HIF1A (0.41) | MEN1KMT2ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL11846749 | 0.80 | HIF1A (0.41) | MEN1KMT2ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL596253 | 0.79 | HIF1A (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3HIF1A | |
| SCHEMBL8914673 | 0.76 | MEN1 (0.41) | MEN1KMT2ACHRNB2CHRNA4HIF1A | |
| SCHEMBL5509200 | 0.74 | ACHE (0.37) | MEN1KMT2ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL6926932 | 0.68 | SIGMAR1 (0.46) | MEN1KMT2AGBA1HIF1ACYP2D6 | |
| SCHEMBL1702299 | 0.68 | HIF1A (0.37) | MEN1KMT2AHIF1ACYP2D6 | |
| Hydrochloric Acid SCHEMBL10944858 | 0.67 | SIGMAR1 (0.44) | MEN1KMT2AGBA1HIF1ACHRM2 | |
| SCHEMBL6280980 | 0.67 | HIF1A (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3HIF1A | |
| (Chloromethyl)Benzene SCHEMBL10945678 | 0.65 | ALDH1A1 (0.41) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | MEN1 4157/4885KMT2A 2856/4885CHRNB2 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.